Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

NCT03066648 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Decitabine
DRUG: PDR001
DRUG: MBG453
DRUG: Azacitidine

Sponsor

Novartis Pharmaceuticals